Cargando…

Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas

Vesicular monoamine transporter 2 (VMAT2) is expressed in pancreatic beta cells and has recently been proposed as a target for measurement of beta cell mass in vivo. We questioned, (1) What proportion of beta cells express VMAT2? (2) Is VMAT2 expressed by other pancreatic endocrine or non-endocrine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saisho, Yoshifumi, Harris, Paul E., Butler, Alexandra E., Galasso, Ryan, Gurlo, Tatyana, Rizza, Robert A., Butler, Peter C.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2008
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566800/ https://www.ncbi.nlm.nih.gov/pubmed/18791800 http://dx.doi.org/10.1007/s10735-008-9195-9

Ejemplares similares

Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas
por: Freeby, Matthew, et al.
Publicado: (2012)

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions
por: Alwindi, Malik, et al.
Publicado: (2023)

Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing
por: Lohoff, Falk W., et al.
Publicado: (2013)

No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease
por: Tian, LinLin, et al.
Publicado: (2012)

Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population
por: Richards, Misty, et al.
Publicado: (2006)

The ins and outs of vesicular monoamine transporters
por: Yaffe, Dana, et al.
Publicado: (2018)

Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent
por: Jiang, Donglang, et al.
Publicado: (2019)

Dopamine D(1), D(2), D(3) Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain
por: Sun, Jianjun, et al.
Publicado: (2012)

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2013)

Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse
por: König, Niclas, et al.
Publicado: (2020)

Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019)

Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes
por: Saisho, Y, et al.
Publicado: (2007)

An Acidic Motif Retains Vesicular Monoamine Transporter 2 on Large Dense Core Vesicles
por: Waites, Clarissa L., et al.
Publicado: (2001)

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
por: Caroff, Stanley N.
Publicado: (2020)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
por: Butler, Alexandra E., et al.
Publicado: (2013)

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients
por: Xu, San San, et al.
Publicado: (2018)

Relationship between fractional pancreatic beta cell area and fasting plasma glucose concentration in monkeys
por: Saisho, Y., et al.
Publicado: (2009)

Pancreatic duct replication is increased with obesity and type 2 diabetes in humans
por: Butler, A. E., et al.
Publicado: (2009)

Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice
por: Baumann, Aron, et al.
Publicado: (2016)

A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders
por: NIKKHAH, Ali
Publicado: (2021)

Ongoing β-Cell Turnover in Adult Nonhuman Primates Is Not Adaptively Increased in Streptozotocin-Induced Diabetes
por: Saisho, Yoshifumi, et al.
Publicado: (2011)

Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604
por: Butler, Alexandra E., et al.
Publicado: (2013)

Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men
por: Yang, Xinglong, et al.
Publicado: (2015)

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2
por: Huang, Zih-Rou, et al.
Publicado: (2016)

Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism
por: Beauchamp, Leah C., et al.
Publicado: (2020)

Differential Localization of Vesicular Acetylcholine and Monoamine Transporters in PC12 Cells but Not CHO Cells
por: Liu, Yongjian, et al.
Publicado: (1997)

A Glial Variant of the Vesicular Monoamine Transporter Is Required To Store Histamine in the Drosophila Visual System
por: Romero-Calderón, Rafael, et al.
Publicado: (2008)

Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats
por: Hiranita, Takato
Publicado: (2015)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

β-Cell Mass and Turnover in Humans: Effects of obesity and aging
por: Saisho, Yoshifumi, et al.
Publicado: (2013)

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin
por: Matveyenko, Aleksey V., et al.
Publicado: (2009)

A Functional Vesicular Monoamine Transporter 1 (VMAT1) Gene Variant Is Associated with Affect and the Prevalence of Anxiety, Affective, and Alcohol Use Disorders in a Longitudinal Population-Representative Birth Cohort Study
por: Vaht, Mariliis, et al.
Publicado: (2016)

Low Grade Islet but Marked Exocrine Pancreas Inflammation in an Adult with Autoimmune Pre-Diabetes
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

β-Cell Dysfunctional ERAD/Ubiquitin/Proteasome System in Type 2 Diabetes Mediated by Islet Amyloid Polypeptide–Induced UCH-L1 Deficiency
por: Costes, Safia, et al.
Publicado: (2011)

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells
Publicado: (1994)

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET
por: Lin, Kun-Ju, et al.
Publicado: (2013)

Successful Versus Failed Adaptation to High-Fat Diet–Induced Insulin Resistance: The Role of IAPP-Induced β-Cell Endoplasmic Reticulum Stress
por: Matveyenko, Aleksey V., et al.
Publicado: (2009)

Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
por: Inaishi, Jun, et al.
Publicado: (2020)

Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens
por: David, H N, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dr43hkbi9vqjrjiiheoeg9maie